Author:
Krawczyk Natalia,Banys-Paluchowski Malgorzata,Meier Werner,Volkmer Anne-Kathrin,Fehm Tanja
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology
Reference31 articles.
1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Kurzversion 3.0, 2019, AWMF-Registrierungsnummer: 032-035OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/ovarialkarzinom/. Zugegriffen: 15. Okt. 2019
2. Drew Y et al (2019) Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Ann. Oncol 30:v485–v486. https://doi.org/10.1093/annonc/mdz253.016
3. Buttmann-Schweiger N, Kraywinkel K (2019) Epidemiologie von Eierstockkrebs in Deutschland. Onkologe 25(2):92–98
4. Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949
5. Drew Y, de Jonge M, Hong SH et al (2018) An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline 〈em〉BRCA〈/em〉-mutated (〈em〉gBRCA〈/em〉m) platinum-sensitive relapsed (PSR) ovarian cancer (OC). Gynecol Oncol 149:246–247